Department of Endocrinology, Medwin Hospitals, Hyderabad, Andhra Pradesh, India.
Endocr Pract. 2012 Mar-Apr;18(2):e32-6. doi: 10.4158/EP11287.CR.
To report the occurrence of pioglitazone-induced reversible valvular regurgitant lesions.
Clinical, laboratory, and imaging data are reported on a patient with known type 2 diabetes mellitus, who was prescribed pioglitazone to achieve better glycemic control.
We present a case report of a 50-year-old woman, in whom diabetes had been diagnosed 5 years previously, who developed severe mitral and aortic regurgitation during 5 months of treatment with pioglitazone along with clinical and laboratory indications of fluid retention. Echocardiography 5 months after discontinued use of pioglitazone showed regression of regurgitant lesions and normalization of pertinent laboratory variables.
Five months of treatment with pioglitazone could potentially induce major cardiac valvular dysfunction, which was reversible in our patient. This report emphasizes the importance of carefully monitoring patients during treatment with thiazolidinediones.
报告吡格列酮引起的可逆转的瓣膜反流性病变。
报告了一名已知患有 2 型糖尿病的患者的临床、实验室和影像学数据，该患者开了吡格列酮以实现更好的血糖控制。
我们报告了一例 50 岁女性的病例，该患者 5 年前被诊断为糖尿病，在使用吡格列酮治疗 5 个月期间出现严重的二尖瓣和主动脉瓣反流，伴有液体潴留的临床和实验室指征。停用吡格列酮 5 个月后的超声心动图显示反流性病变消退，相关实验室变量正常化。
吡格列酮治疗 5 个月可能会导致心脏主要瓣膜功能障碍，在我们的患者中是可逆的。本报告强调了在使用噻唑烷二酮类药物治疗期间仔细监测患者的重要性。
